The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.

HIV-1 establishes infection in astrocytes and macroage-lineage cells of the central nervous system (CNS). Certain antiretroviral drugs (ARVs) can penetrate the CNS, and are therefore often used in neurologically active combined antiretroviral therapy (Neuro-cART) regimens, but their relative activit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lachlan R Gray, Gilda Tachedjian, Anne M Ellett, Michael J Roche, Wan-Jung Cheng, Gilles J Guillemin, Bruce J Brew, Stuart G Turville, Steve L Wesselingh, Paul R Gorry, Melissa J Churchill
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d97c6377d27544618061aac3fbdc631d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d97c6377d27544618061aac3fbdc631d
record_format	dspace
spelling	oai:doaj.org-article:d97c6377d27544618061aac3fbdc631d2021-11-18T07:49:11ZThe NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.1932-620310.1371/journal.pone.0062196https://doaj.org/article/d97c6377d27544618061aac3fbdc631d2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23614033/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203HIV-1 establishes infection in astrocytes and macroage-lineage cells of the central nervous system (CNS). Certain antiretroviral drugs (ARVs) can penetrate the CNS, and are therefore often used in neurologically active combined antiretroviral therapy (Neuro-cART) regimens, but their relative activity in the different susceptible CNS cell populations is unknown. Here, we determined the HIV-1 inhibitory activity of CNS-penetrating ARVs in astrocytes and macrophage-lineage cells. Primary human fetal astrocytes (PFA) and the SVG human astrocyte cell line were used as in vitro models for astrocyte infection, and monocyte-derived macrophages (MDM) were used as an in vitro model for infection of macrophage-lineage cells. The CNS-penetrating ARVs tested were the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir (ABC), lamivudine (3TC), stavudine (d4T) and zidovudine (ZDV), the non-NRTIs efavirenz (EFV), etravirine (ETR) and nevirapine (NVP), and the integrase inhibitor raltegravir (RAL). Drug inhibition assays were performed using single-round HIV-1 entry assays with luciferase viruses pseudotyped with HIV-1 YU-2 envelope or vesicular stomatitis virus G protein (VSV-G). All the ARVs tested could effectively inhibit HIV-1 infection in macrophages, with EC90s below concentrations known to be achievable in the cerebral spinal fluid (CSF). Most of the ARVs had similar potency in astrocytes, however the NRTIs 3TC, d4T and ZDV had insufficient HIV-1 inhibitory activity in astrocytes, with EC90s 12-, 187- and 110-fold greater than achievable CSF concentrations, respectively. Our data suggest that 3TC, d4T and ZDV may not adequately target astrocyte infection in vivo, which has potential implications for their inclusion in Neuro-cART regimens.Lachlan R GrayGilda TachedjianAnne M EllettMichael J RocheWan-Jung ChengGilles J GuilleminBruce J BrewStuart G TurvilleSteve L WesselinghPaul R GorryMelissa J ChurchillPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 4, p e62196 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lachlan R Gray Gilda Tachedjian Anne M Ellett Michael J Roche Wan-Jung Cheng Gilles J Guillemin Bruce J Brew Stuart G Turville Steve L Wesselingh Paul R Gorry Melissa J Churchill The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
description	HIV-1 establishes infection in astrocytes and macroage-lineage cells of the central nervous system (CNS). Certain antiretroviral drugs (ARVs) can penetrate the CNS, and are therefore often used in neurologically active combined antiretroviral therapy (Neuro-cART) regimens, but their relative activity in the different susceptible CNS cell populations is unknown. Here, we determined the HIV-1 inhibitory activity of CNS-penetrating ARVs in astrocytes and macrophage-lineage cells. Primary human fetal astrocytes (PFA) and the SVG human astrocyte cell line were used as in vitro models for astrocyte infection, and monocyte-derived macrophages (MDM) were used as an in vitro model for infection of macrophage-lineage cells. The CNS-penetrating ARVs tested were the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir (ABC), lamivudine (3TC), stavudine (d4T) and zidovudine (ZDV), the non-NRTIs efavirenz (EFV), etravirine (ETR) and nevirapine (NVP), and the integrase inhibitor raltegravir (RAL). Drug inhibition assays were performed using single-round HIV-1 entry assays with luciferase viruses pseudotyped with HIV-1 YU-2 envelope or vesicular stomatitis virus G protein (VSV-G). All the ARVs tested could effectively inhibit HIV-1 infection in macrophages, with EC90s below concentrations known to be achievable in the cerebral spinal fluid (CSF). Most of the ARVs had similar potency in astrocytes, however the NRTIs 3TC, d4T and ZDV had insufficient HIV-1 inhibitory activity in astrocytes, with EC90s 12-, 187- and 110-fold greater than achievable CSF concentrations, respectively. Our data suggest that 3TC, d4T and ZDV may not adequately target astrocyte infection in vivo, which has potential implications for their inclusion in Neuro-cART regimens.
format	article
author	Lachlan R Gray Gilda Tachedjian Anne M Ellett Michael J Roche Wan-Jung Cheng Gilles J Guillemin Bruce J Brew Stuart G Turville Steve L Wesselingh Paul R Gorry Melissa J Churchill
author_facet	Lachlan R Gray Gilda Tachedjian Anne M Ellett Michael J Roche Wan-Jung Cheng Gilles J Guillemin Bruce J Brew Stuart G Turville Steve L Wesselingh Paul R Gorry Melissa J Churchill
author_sort	Lachlan R Gray
title	The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
title_short	The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
title_full	The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
title_fullStr	The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
title_full_unstemmed	The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
title_sort	nrtis lamivudine, stavudine and zidovudine have reduced hiv-1 inhibitory activity in astrocytes.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/d97c6377d27544618061aac3fbdc631d
work_keys_str_mv	AT lachlanrgray thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT gildatachedjian thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT annemellett thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT michaeljroche thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT wanjungcheng thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT gillesjguillemin thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT brucejbrew thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT stuartgturville thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT stevelwesselingh thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT paulrgorry thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT melissajchurchill thenrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT lachlanrgray nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT gildatachedjian nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT annemellett nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT michaeljroche nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT wanjungcheng nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT gillesjguillemin nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT brucejbrew nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT stuartgturville nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT stevelwesselingh nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT paulrgorry nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes AT melissajchurchill nrtislamivudinestavudineandzidovudinehavereducedhiv1inhibitoryactivityinastrocytes
_version_	1718422940541779968

The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.

Ejemplares similares